Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dinutuximab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 30 and under at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2009-01064, CDR0000069018, COG-ANBL0032, ANBL0032, U10CA180886, U10CA030969, U10CA098543, COG-P9842, NCT00026312
Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 20 at diagnosis
Sponsor: Other
Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 month to 21 years
Sponsor: Other
Protocol IDs: HR-NBL-1.7 / SIOPEN, NCT01704716
Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: 012010, 2009-018077-31, NCT01701479
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Under 18
Sponsor: Other
Protocol IDs: HSJD-HR-NB-Ch14.18, NCT02169609
CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Less than or equal to 21 years
Sponsor: Other
Protocol IDs: EudraCT:2009-015936-14, NCT02258815
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-02011, N2011-04, NANT 11-04, CDR0000741991, NANT 2011-04, NANT N2011-04, P01CA081403, NCT01711554
Start Over